Literature DB >> 19017463

Apocynin: a potent NADPH oxidase inhibitor for the management of atrial fibrillation.

Ali A Sovari1, Norishige Morita, Hrayr S Karagueuzian.   

Abstract

Oxidative stress in atrial tissue may be causally related to atrial fibrillation as suggested by clinical and animal studies. Reactive oxygen species (ROS) are known to play a key role in fibrosis and the induction of after-depolarization and triggered activity. Therefore, suppressing oxidative stress may have a potential beneficial role in the management of atrial fibrillation. Since increased NADPH oxidase activity is shown to play a key role in generation of ROS in atrial tissue and in atrial fibrillation, our proposed strategy to target upstream inhibition of ROS production by inhibition of NADPH oxidase activity may provide a novel approach to prevent atrial fibrillation recurrences. We hypothesize that apocynin could be effective against atrial fibrillation, by virtue of its potent inhibitory effect of a major oxidative system (i.e. NADPH oxidase) combined with its demonstrated anti-inflammatory, antifibrotic and antihypertensive effects which partially are driven from its antioxidant property. Atrial fibrillation is known to be initiated by the interaction of these multiple factors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19017463     DOI: 10.1179/135100008X309000

Source DB:  PubMed          Journal:  Redox Rep        ISSN: 1351-0002            Impact factor:   4.412


  10 in total

1.  Angiotensin II induces afterdepolarizations via reactive oxygen species and calmodulin kinase II signaling.

Authors:  Zhenghang Zhao; Nadezhda Fefelova; Mayilvahanan Shanmugam; Peter Bishara; Gopal J Babu; Lai-Hua Xie
Journal:  J Mol Cell Cardiol       Date:  2010-11-06       Impact factor: 5.000

Review 2.  Antioxidant therapies for the management of atrial fibrillation.

Authors:  Tong Liu; Panagiotis Korantzopoulos; Guangping Li
Journal:  Cardiovasc Diagn Ther       Date:  2012-12

3.  Mitoapocynin Treatment Protects Against Neuroinflammation and Dopaminergic Neurodegeneration in a Preclinical Animal Model of Parkinson's Disease.

Authors:  Anamitra Ghosh; Monica R Langley; Dilshan S Harischandra; Matthew L Neal; Huajun Jin; Vellareddy Anantharam; Joy Joseph; Timothy Brenza; Balaji Narasimhan; Arthi Kanthasamy; Balaraman Kalyanaraman; Anumantha G Kanthasamy
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-02       Impact factor: 4.147

4.  Reactive oxygen species-targeted therapeutic interventions for atrial fibrillation.

Authors:  Ali A Sovari; Samuel C Dudley
Journal:  Front Physiol       Date:  2012-08-06       Impact factor: 4.566

5.  Antioxidant therapy for atrial fibrillation: what is the next step?

Authors:  Ali A Sovari
Journal:  Cardiol Res Pract       Date:  2011-11-03       Impact factor: 1.866

6.  Apocynin attenuates left ventricular remodeling in diabetic rabbits.

Authors:  Jiuchun Qiu; Jianping Zhao; Jian Li; Xue Liang; Yajuan Yang; Zhiwei Zhang; Xiaowei Zhang; Huaying Fu; Panagiotis Korantzopoulos; Gary Tse; Tong Liu; Guangping Li
Journal:  Oncotarget       Date:  2017-06-13

7.  Enhanced cardiomyocyte reactive oxygen species signaling promotes ibrutinib-induced atrial fibrillation.

Authors:  Xinyu Yang; Na An; Changming Zhong; Manke Guan; Yuchen Jiang; Xinye Li; Hanlai Zhang; Liqin Wang; Yanfei Ruan; Yonghong Gao; Nian Liu; Hongcai Shang; Yanwei Xing
Journal:  Redox Biol       Date:  2020-01-20       Impact factor: 11.799

Review 8.  Role of Oxidative DNA Damage and Repair in Atrial Fibrillation and Ischemic Heart Disease.

Authors:  Liangyu Hu; Zhengkun Wang; Claudia Carmone; Jaap Keijer; Deli Zhang
Journal:  Int J Mol Sci       Date:  2021-04-07       Impact factor: 5.923

9.  Antioxidant therapy for atrial fibrillation: lost in translation?

Authors:  Ali A Sovari; S C Dudley
Journal:  Heart       Date:  2012-08-15       Impact factor: 5.994

10.  Induction of atrial fibrillation by neutrophils critically depends on CD11b/CD18 integrins.

Authors:  Kai Friedrichs; Matti Adam; Lisa Remane; Martin Mollenhauer; Volker Rudolph; Tanja K Rudolph; René P Andrié; Florian Stöckigt; Jan W Schrickel; Thorben Ravekes; Florian Deuschl; Georg Nickenig; Stephan Willems; Stephan Baldus; Anna Klinke
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.